Teladoc Health, Inc. (NYSE:TDOC – Get Rating) reached a new 52-week low on Thursday after Royal Bank of Canada lowered their price target on the stock from $53.00 to $35.00. The stock traded as low as $26.08 and last traded at $26.51, with a volume of 60514 shares changing hands. The stock had previously closed at $28.20.

Several other equities analysts also recently weighed in on the company. Truist Financial began coverage on Teladoc Health in a research report on Wednesday, September 7th. They issued a "hold" rating and a $35.00 target price for the company. Canaccord Genuity Group decreased their price objective on Teladoc Health from $50.00 to $45.00 in a research note on Thursday, July 28th. Bank of America lifted their price objective on Teladoc Health from $36.00 to $42.00 and gave the company a "neutral" rating in a research note on Wednesday, July 6th. SVB Leerink decreased their price objective on Teladoc Health from $35.00 to $34.00 and set a "market perform" rating for the company in a research note on Thursday, July 28th. Finally, Barclays decreased their price objective on Teladoc Health from $45.00 to $42.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 20th. Two research analysts have rated the stock with a sell rating, twenty-four have given a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $64.13.

Insider Buying and Selling at Teladoc Health

In other news, SVP Daniel Trencher sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $37.50, for a total value of $37,500.00. Following the transaction, the senior vice president now owns 26,408 shares of the company's stock, valued at $990,300. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Arnnon Geshuri sold 4,098 shares of the business's stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $34.27, for a total value of $140,438.46. Following the transaction, the insider now owns 76,182 shares of the company's stock, valued at $2,610,757.14. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Daniel Trencher sold 1,000 shares of the company's stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $37.50, for a total value of $37,500.00. Following the transaction, the senior vice president now directly owns 26,408 shares in the company, valued at approximately $990,300. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,318 shares of company stock worth $255,321. 1.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Teladoc Health Price Performance

The stock has a fifty day moving average of $33.75 and a two-hundred day moving average of $41.67. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of -0.43 and a beta of 0.86. The company has a quick ratio of 3.22, a current ratio of 3.38 and a debt-to-equity ratio of 0.25.

Teladoc Health (NYSE:TDOC – Get Rating) last posted its earnings results on Wednesday, July 27th. The health services provider reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.27. The company had revenue of $592.38 million for the quarter, compared to the consensus estimate of $586.86 million. Teladoc Health had a negative return on equity of 2.04% and a negative net margin of 441.94%. On average, equities research analysts anticipate that Teladoc Health, Inc. will post -1.54 earnings per share for the current year.

Teladoc Health Company Profile

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Recommended Stories

• Get a free copy of the StockNews.com research report on Teladoc Health (TDOC)
• Humana Proves Vertically Integrated Healthcare Works
• What Cintas Can Teach Investors About This Bear Market?
• This Small-Cap Healthcare Name Is Outperforming Its Index
• 2 Casino Stocks Worth Taking a Look At
• Blackberry Stock Declines As Results Come In Lukewarm Once Again

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.